SCHEMBL336148

SCHEMBL336148

COc1ccc(O[Si](C)(C)C(C)(C)C)c(CC2CO2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.39
ADRA1A P35348 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
TP53 P04637 3/20 0.35
HTT P42858 1/20 0.35
PTPN1 P18031 1/20 0.35
MAPT P10636 3/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP1A2 P05177 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PPARG P37231 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403969 0.82 IDO1 (0.42) IDO1ADRA1ATAAR1MAPTHSD17B10
SCHEMBL1027826 0.82 IDO1 (0.42) IDO1ADRA1ATAAR1MAPTHSD17B10
SCHEMBL16535794 0.80 IDO1 (0.45) IDO1ADRA1ATAAR1GAAHSD17B10
SCHEMBL16536259 0.79 IDO1 (0.44) IDO1ADRA1ATAAR1HSD17B10ALDH1A1
SCHEMBL334513 0.79 ALDH1A1 (0.41) TP53MAPTMEN1HPGDTSHR
SCHEMBL27443840 0.76 SLC6A2 (0.46) IDO1ADRA1ATAAR1HSD17B10HTR2A
SCHEMBL6049292 0.75 ALDH1A1 (0.49) TP53PTPN1MAPTMEN1HPGD
SCHEMBL13640332 0.74 CA12 (0.59) IDO1MAPTMEN1KMT2ACYP1A2
SCHEMBL7286280 0.73 PREP (0.41) TP53MAPTMEN1HPGDTSHR
SCHEMBL9826250 0.72 PKM (0.38) IDO1ADRA1ATAAR1PTPN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 IDO1 1290/4885ADRA1A 3144/4885TAAR1 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.